Acharya Balakrishna, Patanjali's chief executive officer, who was sued for treating covid last week, claimed on Tuesday that the company had never claimed that its newly-tested drugs would treat coronavirus.
The company's chief executive told reporters on Tuesday that the conspiracy was hatched after the company responded to a notice from the Uttarakhand Drug Regulatory Board. At least one FIR has been lodged alleging misleading the company. The Uttarakhand High Court on Tuesday also issued notice to the Center on the application filed by the company.
Balakrishna said the company has never claimed to have developed a cure for Kovid.
"We cite coronil as an ayurvedic medicine for boosting the immune system, fever, cough and allergic problems," Balakrishna said. He stressed that the company had only pointed out that clinical trials indicated that Covid-19 patients, when given the drug, recovered.
"The results of the clinical trial-based treatment of positive patients were claimed by us," he said.
Balakrishna's claim and attempt to distance himself from the vision contradicts his Twitter timeline where he retweeted news reports and congratulatory messages to find a cure for Kovid-19. Or he and Baba Ramdev have been making a lot of statements in the last fortnight.
See | Never said that coronal covid can cure patients': Patanjali CEO Balakrishna
"The whole country and the world was waiting for a medicine or a vaccine for Corona. "We are proud to announce that the first Ayurvedic, clinically controlled trial-based evidence-based and research-based medicine has been developed through the joint efforts of Patanjali Research Center and NIMS," Yoga Guru Ramdev told a press conference on June 23.
Also read | ‘All parameters found’: Patanjali claims coronal clinical trial details given at center
That claim made headlines in India. But it also caught the attention of regulatory officials who felt that Patanjali had not sought the necessary approvals from state or central authorities. The Union AYUSH ministry had issued haphazard orders, barring Patanjali from announcing his claim before the approvals came into force.
The first indication of the company's changing stance came a day after the company's announcement about clinical trials. The Ayurveda department in Uttarakhand later announced that Patanjali had applied for a license to manufacture not only Kovid-19 but also an immune booster.